title: Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
abstract: BACKGROUND
  Proton pump inhibitor (PPI) medications have been inconsistently shown to be associated with osteoporotic fractures. We examined the association of PPI use with bone outcomes (fracture, bone mineral density [BMD]).
  
  
  METHODS
  This prospective analysis included 161 806 postmenopausal women 50 to 79 years old, without history of hip fracture, enrolled in the Women's Health Initiative (WHI) Observational Study and Clinical Trials with a mean (SD) follow-up of 7.8 (1.6) years. Analyses were conducted for 130 487 women with complete information. Medication information was taken directly from drug containers during in-person interviews (baseline, year 3). The main outcome measures were self-reported fractures (hip [adjudicated], clinical spine, forearm or wrist, and total fractures) and for a subsample (3 densitometry sites), 3-year change in BMD.
  
  
  RESULTS
  During 1 005 126 person-years of follow-up, 1500 hip fractures, 4881 forearm or wrist fractures, 2315 clinical spine fractures, and 21 247 total fractures occurred. The multivariate-adjusted hazard ratios for current PPI use were 1.00 (95% confidence interval [CI], 0.71-1.40) for hip fracture, 1.47 (95% CI, 1.18-1.82) for clinical spine fracture, 1.26 (95% CI, 1.05-1.51) for forearm or wrist fracture, and 1.25 (95% CI, 1.15-1.36) for total fractures. The BMD measurements did not vary between PPI users and nonusers at baseline. Use of PPIs was associated with only a marginal effect on 3-year BMD change at the hip (P = .05) but not at other sites.
  
  
  CONCLUSIONS
  Use of PPIs was not associated with hip fractures but was modestly associated with clinical spine, forearm or wrist, and total fractures.
authors.affiliation: School of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA. slgray@u.washington.edu
authors.forename: Shelly L
authors.initials: SL
authors.lastname: Gray
authors.forename: Andrea Z
authors.initials: AZ
authors.lastname: LaCroix
authors.forename: Joseph
authors.initials: J
authors.lastname: Larson
authors.forename: John
authors.initials: J
authors.lastname: Robbins
authors.forename: Jane A
authors.initials: JA
authors.lastname: Cauley
authors.forename: JoAnn E
authors.initials: JE
authors.lastname: Manson
authors.forename: Zhao
authors.initials: Z
authors.lastname: Chen
mesh_terms: D000368:Aged; D015519:Bone Density / Q000187:drug effects; D005260:Female; D005598:Fractures, Spontaneous / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D010024:Osteoporosis / Q000139:chemically induced* / Q000453:epidemiology; D017698:Postmenopause; D016016:Proportional Hazards Models; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D054328:Proton Pump Inhibitors
references.citation: Calcif Tissue Int. 1986 Feb;38(2):123-5
references.pmid: 3006888
references.citation: Pharmacotherapy. 2008 Aug;28(8):951-9
references.pmid: 18657011
references.citation: Curr Pharm Des. 2002;8(23):2033-48
references.pmid: 12171517
references.citation: Am J Epidemiol. 1997 Nov 15;146(10):856-69
references.pmid: 9384206
references.citation: JAMA. 2006 Dec 27;296(24):2947-53
references.pmid: 17190895
references.citation: Menopause. 2004 May-Jun;11(3):264-74
references.pmid: 15167305
references.citation: Am J Med. 2005 Jul;118(7):778-81
references.pmid: 15989913
references.citation: Artif Organs. 1998 Jul;22(7):569-73
references.pmid: 9684693
references.citation: Nephron. 2002 Jul;91(3):474-9
references.pmid: 12119480
references.citation: Control Clin Trials. 1998 Feb;19(1):61-109
references.pmid: 9492970
references.citation: Ann Epidemiol. 2003 Oct;13(9 Suppl):S107-21
references.pmid: 14575943
references.citation: Med Sci Sports Exerc. 1993 Jan;25(1):71-80
references.pmid: 8292105
references.citation: Calcif Tissue Int. 1993 Jul;53(1):21-5
references.pmid: 8102318
references.citation: Calcif Tissue Int. 2006 Aug;79(2):84-94
references.pmid: 16927048
references.citation: Med Care. 1992 Jun;30(6):473-83
references.pmid: 1593914
references.citation: J Bone Miner Res. 1991 Aug;6(8):865-8
references.pmid: 1785376
references.citation: J Clin Invest. 1984 Mar;73(3):640-7
references.pmid: 6707197
references.citation: J Am Coll Nutr. 1995 Aug;14(4):364-8
references.pmid: 8568113
references.citation: Nephrol Dial Transplant. 1995;10(8):1376-80
references.pmid: 8538929
references.citation: CMAJ. 2008 Aug 12;179(4):319-26
references.pmid: 18695179
references.citation: Calcif Tissue Int. 2008 Oct;83(4):251-9
references.pmid: 18813868
references.citation: JAMA. 2007 Nov 28;298(20):2389-98
references.pmid: 18042916